Better Therapeutics Granted U.S. Patent For Key Features Of Prescription Digital Therapeutics Platform

Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, announced that the U.S. Patent and Trade Office (USPTO) has granted a patent for a number of key features core to the company’s prescription digital therapeutics platform. The platform is designed to help treat cardiometabolic diseases through the delivery of digital behavioral therapy as a PDT. The patent protects the technology through at least September 2039.

The patent was granted on June 7, 2022, as U.S. Patent No. 11,355,228. It covers methods . . .